Skip to main content
Top
Published in: Drugs & Aging 11/2015

01-11-2015 | Original Research Article

Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease

Authors: Heidi Taipale, Hanna Vuorikari, Antti Tanskanen, Marjaana Koponen, Jari Tiihonen, Raimo Kettunen, Sirpa Hartikainen

Published in: Drugs & Aging | Issue 11/2015

Login to get access

Abstract

Purpose

The aim of this study was to analyse the prevalence and predictors of drug combinations increasing bleeding risk among warfarin users with and without Alzheimer’s disease (AD).

Methods

This retrospective observational study utilised data from the Finnish MEDALZ-2005 cohort. The MEDALZ-2005 study included all community-dwelling persons with a clinically verified diagnosis of AD at the end of 2005, and one comparison person without AD for each case. Data on drug use was collected from the Prescription Register. We included persons who were warfarin users during the study period 2006–2009. Drug combinations increasing bleeding risk with warfarin included selective serotonin reuptake inhibitors (SSRIs), non-steroidal anti-inflammatory agents (NSAIDs), other antithrombotic drugs and tramadol. Factors associated with combination use were investigated with logistic regression.

Results

During the follow-up, 3385 persons with AD and 4830 persons without AD used warfarin. Drug combinations increasing bleeding risk were more common in warfarin users with AD than without AD [35.9 and 30.5 %, respectively (p < 0.0001)]. The most common combination was SSRIs and warfarin, which was more common among persons with AD (23.8 %) than among persons without AD (10.9 %). NSAIDs and warfarin combination was more common among persons without AD. Combination use was associated with AD, female gender, younger age, diabetes mellitus, rheumatoid arthritis and asthma/chronic obstructive pulmonary disease (COPD).

Conclusions

Use of drug combinations increasing bleeding risk was more common among warfarin users with AD. Special attention should be paid to minimise the duration of concomitant use and to find safer alternatives without increased bleeding risk.
Literature
1.
go back to reference Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59:635–46.PubMed Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59:635–46.PubMed
3.
go back to reference Sinauridze EI, Panteleev MA, Ataullakhanov FI. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis. 2012;23:482–93.CrossRefPubMed Sinauridze EI, Panteleev MA, Ataullakhanov FI. Anticoagulant therapy: basic principles, classic approaches and recent developments. Blood Coagul Fibrinolysis. 2012;23:482–93.CrossRefPubMed
5.
go back to reference Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7:99–111.CrossRefPubMed Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007;7:99–111.CrossRefPubMed
6.
go back to reference Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161:241–6.CrossRefPubMed Sellers MB, Newby LK. Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients. Am Heart J. 2011;161:241–6.CrossRefPubMed
7.
go back to reference Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost. 2005;94:537–43.PubMed Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost. 2005;94:537–43.PubMed
8.
go back to reference Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125:773–8.CrossRefPubMed Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125:773–8.CrossRefPubMed
9.
go back to reference Van Doorn C, Gruber-Baldini AL, Zimmerman S, Hebel RJ, Port CL, Baumgarten M, et al. Dementia as a risk factor for falls and fall injuries among nursing home residents. J Am Geriatr Soc. 2003;51:1213–8.CrossRefPubMed Van Doorn C, Gruber-Baldini AL, Zimmerman S, Hebel RJ, Port CL, Baumgarten M, et al. Dementia as a risk factor for falls and fall injuries among nursing home residents. J Am Geriatr Soc. 2003;51:1213–8.CrossRefPubMed
10.
go back to reference Douglas A, Letts L, Richardson J. A systematic review of accidental injury from fire, wandering and medication self-administration errors for older adults with and without dementia. Arch Gerontol Geriatr. 2011;52:e1–10.CrossRefPubMed Douglas A, Letts L, Richardson J. A systematic review of accidental injury from fire, wandering and medication self-administration errors for older adults with and without dementia. Arch Gerontol Geriatr. 2011;52:e1–10.CrossRefPubMed
11.
go back to reference Tolppanen A-M, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research—the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study. Clin Epidemiol. 2013;5:277–85.PubMedCentralCrossRefPubMed Tolppanen A-M, Taipale H, Koponen M, Lavikainen P, Tanskanen A, Tiihonen J, et al. Use of existing data sources in clinical epidemiology: Finnish health care registers in Alzheimer’s disease research—the Medication use among persons with Alzheimer’s disease (MEDALZ-2005) study. Clin Epidemiol. 2013;5:277–85.PubMedCentralCrossRefPubMed
12.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.CrossRefPubMed McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.CrossRefPubMed
14.
go back to reference Taipale H, Tanskanen A, Koponen M, Tolppanen A-M, Tiihonen J, Hartikainen S. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29:216–23.PubMedCentralCrossRefPubMed Taipale H, Tanskanen A, Koponen M, Tolppanen A-M, Tiihonen J, Hartikainen S. Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland: a nationwide register-based study. Int Clin Psychopharmacol. 2014;29:216–23.PubMedCentralCrossRefPubMed
15.
go back to reference Taipale H, Koponen M, Tanskanen A, Tolppanen A-M, Tiihonen J, Hartikainen S. Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. J Clin Psychopharmacol. 2014;34:435–40.CrossRefPubMed Taipale H, Koponen M, Tanskanen A, Tolppanen A-M, Tiihonen J, Hartikainen S. Antipsychotic doses among community-dwelling persons with Alzheimer disease in Finland. J Clin Psychopharmacol. 2014;34:435–40.CrossRefPubMed
16.
go back to reference Taipale H, Koponen M, Tanskanen A, Tolppanen A-M, Tiihonen J, Hartikainen S. Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis. 2014;41:1223–8.PubMed Taipale H, Koponen M, Tanskanen A, Tolppanen A-M, Tiihonen J, Hartikainen S. Antipsychotic polypharmacy among a nationwide sample of community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis. 2014;41:1223–8.PubMed
17.
go back to reference Torvinen-Kiiskinen S, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S. Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among Finnish community-dwelling persons with Alzheimer disease. J Clin Psychopharmacol. 2014;34:1–6.CrossRef Torvinen-Kiiskinen S, Taipale H, Tanskanen A, Tiihonen J, Hartikainen S. Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among Finnish community-dwelling persons with Alzheimer disease. J Clin Psychopharmacol. 2014;34:1–6.CrossRef
18.
go back to reference Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö M-L, et al. SFINX-a drug–drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65:627–33.CrossRefPubMed Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö M-L, et al. SFINX-a drug–drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65:627–33.CrossRefPubMed
19.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
20.
go back to reference Howard PA, Ellerbeck EF, Engelman KK, Patternson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2002;11:569–76.CrossRefPubMed Howard PA, Ellerbeck EF, Engelman KK, Patternson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2002;11:569–76.CrossRefPubMed
21.
go back to reference Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med. 2009;41:619–28.CrossRefPubMed Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med. 2009;41:619–28.CrossRefPubMed
22.
go back to reference Kotirum S, Chaiyakunapruk N, Jampachaisri K, Wattanasombat S, Rojnuckarin P. Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy. Pharmacoepidemiol Drug Saf. 2007;16:216–22.CrossRefPubMed Kotirum S, Chaiyakunapruk N, Jampachaisri K, Wattanasombat S, Rojnuckarin P. Utilization review of concomitant use of potentially interacting drugs in Thai patients using warfarin therapy. Pharmacoepidemiol Drug Saf. 2007;16:216–22.CrossRefPubMed
23.
go back to reference Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004;24:1668–74.CrossRefPubMed Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004;24:1668–74.CrossRefPubMed
24.
go back to reference Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013. doi:10.1136/bmjopen-2012-002080. Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013. doi:10.​1136/​bmjopen-2012-002080.
25.
go back to reference Kessing LV, Harhoff M, Andersen PK. Treatment with antidepressants in patients with dementia-a nationwide register-based study. Int Psychogeriatr. 2007;19:902–13.CrossRefPubMed Kessing LV, Harhoff M, Andersen PK. Treatment with antidepressants in patients with dementia-a nationwide register-based study. Int Psychogeriatr. 2007;19:902–13.CrossRefPubMed
26.
go back to reference Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribingin people with dementia: a populationdatabase study. Age Ageing. 2010;39:637–42.CrossRefPubMed Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribingin people with dementia: a populationdatabase study. Age Ageing. 2010;39:637–42.CrossRefPubMed
28.
go back to reference Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596–608.CrossRefPubMed Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:596–608.CrossRefPubMed
29.
go back to reference Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.PubMedCentralCrossRefPubMed Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006;333:726.PubMedCentralCrossRefPubMed
30.
go back to reference Lip G, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg J, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group. Eur Heart J. 2014;35:3155–79.CrossRefPubMed Lip G, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg J, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group. Eur Heart J. 2014;35:3155–79.CrossRefPubMed
31.
go back to reference Roughead EE, Kalisch LM, Barratt JD, Gilbert AL. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol. 2010;70:252–7.PubMedCentralCrossRefPubMed Roughead EE, Kalisch LM, Barratt JD, Gilbert AL. Prevalence of potentially hazardous drug interactions amongst Australian veterans. Br J Clin Pharmacol. 2010;70:252–7.PubMedCentralCrossRefPubMed
32.
go back to reference Vitry AI, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, et al. Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf. 2011;20:1057–63.CrossRefPubMed Vitry AI, Roughead EE, Ramsay EN, Preiss AK, Ryan P, Gilbert AL, et al. Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf. 2011;20:1057–63.CrossRefPubMed
33.
go back to reference Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost. 2008;100:1076–83.PubMed Schalekamp T, Klungel OH, Souverein PC, de Boer A. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost. 2008;100:1076–83.PubMed
34.
go back to reference Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.CrossRefPubMed Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967–74.CrossRefPubMed
35.
go back to reference Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–92.CrossRefPubMed Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165:189–92.CrossRefPubMed
36.
go back to reference Penning-van Beest F, Erkens J, Petersen K-U, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol. 2005;61:439–44. Penning-van Beest F, Erkens J, Petersen K-U, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol. 2005;61:439–44.
37.
go back to reference Pottegård A, Meegaard PM, Holck LHV, dePont Christensen Rd, Madsen H, Hallas J. Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. Eur J Clin Pharmacol 2013;69:641–6. Pottegård A, Meegaard PM, Holck LHV, dePont Christensen Rd, Madsen H, Hallas J. Concurrent use of tramadol and oral vitamin K antagonists and the risk of excessive anticoagulation: a register-based nested case-control study. Eur J Clin Pharmacol 2013;69:641–6.
38.
go back to reference Brouquet A, Cudennec T, Benoist S, Moulias S, Beauchet A, Penna C, et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg. 2010;251:759–65.CrossRefPubMed Brouquet A, Cudennec T, Benoist S, Moulias S, Beauchet A, Penna C, et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg. 2010;251:759–65.CrossRefPubMed
39.
go back to reference Hughes GJ, Patel PN, Saxena N. Effect of acetaminophen on international normalized ratio in patients receiving warfarin therapy. Pharmacotherapy. 2011;31:591–7.CrossRefPubMed Hughes GJ, Patel PN, Saxena N. Effect of acetaminophen on international normalized ratio in patients receiving warfarin therapy. Pharmacotherapy. 2011;31:591–7.CrossRefPubMed
40.
go back to reference Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs. 2010;10:37–48.CrossRefPubMed Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs. 2010;10:37–48.CrossRefPubMed
42.
go back to reference Quilliam BJ, Lapane KL, Leibson C. Clinical correlates and drug treatment of residents with stroke in long-term care editorial comment. Stroke. 2001;32:1385–93.CrossRefPubMed Quilliam BJ, Lapane KL, Leibson C. Clinical correlates and drug treatment of residents with stroke in long-term care editorial comment. Stroke. 2001;32:1385–93.CrossRefPubMed
43.
go back to reference Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, et al. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.CrossRefPubMed Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, et al. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.CrossRefPubMed
44.
go back to reference Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ Br Med J. 1993;307:846–8.CrossRef Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ Br Med J. 1993;307:846–8.CrossRef
45.
go back to reference Haukka J, Suvisaari J, Tuulio-Henriksson A, Lönnqvist J. High concordance between self-reported medication and official prescription database information. Eur J Clin Pharmacol. 2007;63:1069–74.CrossRefPubMed Haukka J, Suvisaari J, Tuulio-Henriksson A, Lönnqvist J. High concordance between self-reported medication and official prescription database information. Eur J Clin Pharmacol. 2007;63:1069–74.CrossRefPubMed
46.
go back to reference Rikala M, Hartikainen S, Sulkava R, Korhonen MJ. Validity of the Finnish prescription register for measuring psychotropic drug exposures among elderly Finns: a population-based intervention study. Drugs Aging. 2010;27:337–49.CrossRefPubMed Rikala M, Hartikainen S, Sulkava R, Korhonen MJ. Validity of the Finnish prescription register for measuring psychotropic drug exposures among elderly Finns: a population-based intervention study. Drugs Aging. 2010;27:337–49.CrossRefPubMed
Metadata
Title
Prevalence of Drug Combinations Increasing Bleeding Risk Among Warfarin Users With and Without Alzheimer’s Disease
Authors
Heidi Taipale
Hanna Vuorikari
Antti Tanskanen
Marjaana Koponen
Jari Tiihonen
Raimo Kettunen
Sirpa Hartikainen
Publication date
01-11-2015
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 11/2015
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-015-0316-3

Other articles of this Issue 11/2015

Drugs & Aging 11/2015 Go to the issue